Cartesian Therapeutics (RNAC) Receivables (2015 - 2026)

Cartesian Therapeutics (RNAC) has reported Receivables for 12 consecutive years, with $261000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables fell 85.21% year-over-year to $261000.0; the TTM figure through Mar 2026 stood at $261000.0 (down 85.21% YoY), while the FY2025 annual figure was $1.1 million, up 27.87% from the prior year.
• Receivables declined to $261000.0 in Q1 2026 per RNAC's latest filing, from $1.1 million in the prior quarter.
• Across five years, Receivables topped out at $35.5 million in Q2 2024 and bottomed at $261000.0 in Q1 2026.
• Historically, Receivables has averaged $7.6 million across 5 years, with a median of $6.4 million in 2023.
• Annual changes were most pronounced in 2024 — Receivables soared 451.41% — and 2025, when it slumped 99.0%.
• Cartesian Therapeutics' Receivables stood at $9.8 million in 2022, then declined by 9.29% to $8.9 million in 2023, then slumped by 90.15% to $872000.0 in 2024, then increased by 27.87% to $1.1 million in 2025, then plunged by 76.59% to $261000.0 in 2026.
• Business Quant data shows RNAC's Receivables at $261000.0 in Q1 2026, $1.1 million in Q4 2025, and $722000.0 in Q3 2025.